ALSO NOTED: ESC companies unimpressed by latest advance; Delcath shares surge in trial resumption; Pharmion CEO ready to start

> News that scientists had found a way to program skin cells to act like embryonic stem cells has failed to shake the clinical trial plans of the leading developers in the field. Report

> Shares of Delcath Systems surged on the news that the FDA approved resumption of clinical trials of its perfusion delivery technology. Report

> At 44, Pharmion co-founder and CEO Pat Mahaffy says he plans to start a new biotech company after Celgene completes its buyout. Report

> Exelixis has sold an 80 percent stake in Artemis Pharmaceuticals to Taconic Farms for $20 million. Artemis develops and markets genetically engineered mouse models and engineered mouse embryonic stem cells as genetic model systems for use in drug discovery or academic research. Report

> Cerus is spinning off its immunotherapy business. Report

> The FDA has extended its action date on Spectrum Pharmaceuticals' ISO-Vorin or levofolinic acid or LFA for injection NDA by 60 days. Report

And Finally… There's new evidence that the best way to stay mentally tough is to give your brain a regular workout. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.